ID™ SARS-CoV2 / Influenza Triplex is a ready-to-use RT-qPCR in vitro diagnostic test for the qualitative detection of SARS-CoV-2 and Influenza A/B viral RNA after extraction from patient samples.
This qualitative triplex system enables specific and simultaneous amplification of the target RNAs (SARS-CoV-2 and Influenza A/B) for each sample, as well as an endogenous control.
This test differentiates seasonal influenza from SARS-CoV-2 infection.
This detection system targets:
– two sequences specific to the SARS-CoV-2 coronavirus, one encoding the nucleocapsid protein (N) and one encoding RNA polymerase (RdRp), and enables a high level of specificity.
– an Influenza A virus-specific sequence encoding the matrix protein (MP), and an Influenza B virus-specific sequence encoding the non-structural proteins (NSP), and enables simultaneous detection of influenza A and B viruses.
A positive extraction control (PEC) is used to validate the extraction and reverse transcription processes.
Un An endogenous control, corresponding to a human coding gene, is used to evaluate the presence of nucleic acids to be tested, the implementation of the entire procedure, and to assess whether any inhibitors are affecting the amplification phase.
Intended for in vitro diagnostic use (CE-IVD).
Samples
RNA extracted from :
Technology
Protocol lead time
~ 1h00
Storage T°C
-16°C to -26°C
Targets
Detection of two sequences specific to SARS-CoV-2 (N and RdRP) and Influenza A and B viruses
Controls
Positive Extraction Control (PEC)
Positive Amplification Control (PAC)
Endogenous control
Shelf life
Certification
©
All rights reserved
585 Rue de la Croix Verte
34090 MONTPELLIER
+33 (0)4 67 79 72 60
Monday to Friday
9h00 – 12h30 / 14h00 – 17h30
